6-((5, 6-diphenyl-1, 2, 4-triazine-3-yl) (isopropyl) amino)-N-(methylsulfonyl) hexanamide crystal form B as well as application and preparation method of 6-((5, 6-diphenyl-1, 2, 4-triazine-3-yl) (isopropyl) amino)-N-(methylsulfonyl) hexanamide crystal form B

The invention discloses a crystal form B of a compound I (6-((5, 6-diphenyl-1, 2, 4-triazine-3-yl) (isopropyl) amino)-N-(methylsulfonyl) hexanamide) as well as a pharmaceutical composition, application and a preparation method thereof. The compound I crystal form B has diffraction peaks at least at the following diffraction angles 2theta: 3.36 +/-0.2 degrees, 10.07 +/-0.2 degrees, 13.90 +/-0.2 degrees, 16.51 +/-0.2 degrees, 20.20 +/-0.2 degrees and 21.10 +/-0.2 degrees in an X-ray powder diffraction pattern. The compound I crystal form B has the advantages of low hygroscopicity, good stability and the like, and has very important significance on drug development. 本发明公开了一种化合物I(6-((5,6-二苯基-1,2,4-三嗪-3-基)(异丙基)氨基)-N-(甲基磺酰基)己酰胺)晶型B及其药物组合物、用途和制备方法。本发明中所述的化合物I晶型B在其X-射线粉末衍射图中至少在下述衍射角2θ：3.36±0.2°、10.07±0.2°、13.90±0.2°、16.51±0.2°、20.20±0.2°、21.10±0.2°处有衍射峰。本发明的化合物I晶型B具有引湿性低和稳定性好等优点，对于药物开发具有非常重要的意义。